Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats

Abstract

A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.

What is claimed: 
     
         1 . A method for the prophylaxis or treatment of hypertension in a cat in need of such prophylaxis or treatment, the method comprising administering a therapeutically effective amount of an angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, wherein the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period. 
     
     
         2 . The method of  claim 1 , wherein the hypertension is associated with chronic kidney disease or hyperthyroidism. 
     
     
         3 . The method of  claim 1 , wherein the hypertension is idiopathic hypertension. 
     
     
         4 . The method of  claim 1 , wherein the daily dosage amount is varied based upon a systolic blood pressure (SBP) value measured for the cat. 
     
     
         5 . The method of  claim 1 , wherein the daily dosage amount of the sartan is decreased for the second period of time by an incremental amount ranging from 0.10 to 0.50 mg/kg of body weight. 
     
     
         6 . The method of  claim 5 , wherein the daily dosage amount of the sartan is decreased when a systolic blood pressure (SBP) value measured for the cat decreases by at least 10 mmHg, or at least 20 mmHg, or by 10 to 150 mmHg, 10 to 100 mmHg, 10 to 80 mmHg, 10 to 50 mmHg, 10 to 30 mmHg, 10 to 20 mmHg, 20 to 150 mmHg, 20 to 100 mmHg, 20 to 80 mmHg, 20 to 50 mmHg, or 20 to 30 mmHg in relation to a baseline SBP value measured for the cat prior to the first period of time. 
     
     
         7 . The method of  claim 1 , wherein the daily dosage amount of the sartan is decreased when a systolic blood pressure (SBP) value measured for the cat decreases from a baseline SBP value measured for the cat prior to the first period of time to (at or below) a threshold value. 
     
     
         8 . The method of  claim 7 , wherein the threshold value is 160 or 170 mmHg. 
     
     
         9 . The method of  claim 1 , wherein the daily dosage amount of the sartan for the second period of time is increased or decreased for a third period of time after the second period of time and based upon a change in SBP of the cat that is measured at an end of the second period of time. 
     
     
         10 . The method of  claim 1 , wherein the daily dosage amount of the sartan for a first period of time during the treatment period is 2.0 to 3.0 mg/kg of body weight, and the daily dosage amount of the sartan for the second period of time is 0.125 to 2.0 mg/kg of body weight. 
     
     
         11 . The method of  claim 1 , wherein the first period of time is at least 14 days, or at least 28 days, or at least 120 days. 
     
     
         12 . The method of  claim 1 , wherein the daily administration is an oral administration. 
     
     
         13 . The method of  claim 1 , wherein the daily administration of the therapeutically effective amount for at least a portion of the treatment period is provided in a single dose. 
     
     
         14 . The method of  claim 1 , wherein the daily administration of the therapeutically effective amount for at least a portion of the treatment period is provided in a plurality of doses. 
     
     
         15 . The method of  claim 1 , wherein the method excludes administration of the therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat having an age that is less than 9 months or wherein the angiotensin II receptor 1 (AT-1) antagonist (sartan) is administered to a cat at least 9 months of age or wherein the angiotensin II receptor 1 (AT-1) antagonist (sartan) is administered to a cat 9 months of age and older.